Sustained release ranolazine formulations

  • US 6,562,826 B1
  • Filed: 09/25/2002
  • Issued: 05/13/2003
  • Est. Priority Date: 09/10/1998
  • Status: Expired due to Term
First Claim
Patent Images

1. A method for treating a human patient suffering from variant and exercise-induced angina by administering a sustained release ranolazine pharmaceutical dosage form, wherein the dosage form comprises at least 50% by weight ranolazine, said dosage form when administered at least once over a 24 hours period provides a peak to trough plasma ranolazine level ratio that does not exceed 4:

  • 1 over a 24 hour period.

View all claims

    Thank you for your feedback